Results 111 to 120 of about 2,359,106 (231)

Intrinsic colistin resistance [PDF]

The Lancet Infectious Diseases, 2016
Kai, Zhou, Vincent, Cattoir, Yonghong, Xiao   +2 more
openaire   +2 more sources

Real‐World Management of Difficult Exacerbations of Bronchiectasis: A Case Study to Illustrate How Guidelines Can Support Best Practice

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Timely management of exacerbations and optimisation of ongoing care are vital in preventing disease progression and preserving outcomes and quality of life in patients with bronchiectasis. This retrospective case review underscores the importance of the new ERS guidelines in supporting multidisciplinary teams to provide optimal care for their ...
Hulance Bianca, Capstick Toby, Shah Anand, McCallion Paul   +3 more
wiley   +1 more source

Antimicrobial Resistance Mechanisms and Virulence of Colistin- and Carbapenem-Resistant Acinetobacter baumannii Isolated from a Teaching Hospital in Taiwan

, 2021
Acinetobacter baumannii, a Gram-negative bacterium, is an important nosocomial pathogen. Colistin-resistant A. baumannii is becoming a new concern, since colistin is one of the last-line antibiotics for infections by carbapenem-resistant A.
I-Hui Lee, Yuarn-Jang Lee, Shu-Chen Kuo, Noor Andryan Ilsan, Tzu-Wen Huang   +4 more
core   +1 more source

Colistin-resistant Pseudomonas aeruginosa clinical strains with defective biofilm formation

GMS Hygiene and Infection Control, 2019
Aim: Colistin is the only effective antibiotic in some cases of resistance to all tested antibiotics, even carbapenem. On the other hand, biofilm formation is one of the antibiotic resistance mechanisms in this bacterium.
Azimi, Leila, Lari, Abdolaziz Rastegar
doaj   +1 more source

Genomic Insights Into Spatiotemporal Dynamics of Acquired Azithromycin Resistance Genes in Salmonella Strains Worldwide

Food Safety and Health, Volume 4, Issue 4, Page 939-948, October 2026.
ABSTRACT Azithromycin has been used for clinical invasive infections caused by fluoroquinolone‐ and third‐generation cephalosporin‐resistant Salmonella, and mass drug administration with azithromycin has been used to reduce under‐5 mortality in children in some countries.
Yuhang Pei, Mengqi Qu, Ziru Yang, Xuebin Xu, Yanan Wang   +4 more
wiley   +1 more source

Frequency of colistin and fosfomycin resistance in carbapenem-resistant Enterobacteriaceae from a tertiary care hospital in Karachi

, 2017
Salima Qamar, Najma Shaheen, Sadia Shakoor, Joveria Farooqi, Kauser Jabeen, Rumina Hasan Clinical Microbiology, Department of Pathology And Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan Introduction ...
Farooqi J, Hasan R, Jabeen K, Shakoor S, Qamar S, Shaheen N   +5 more
core  

Alteration in the Morphological and Transcriptomic Profiles of Acinetobacter baumannii after Exposure to Colistin

Acinetobacter baumannii is often highly resistant to multiple antimicrobials, posing a risk of treatment failure, and colistin is a “last resort” for treatment of the bacterial infection.
Jung Sik Yoo, Jee-woong Kim, Jun Won Mo, Eun-Jeong Yoon, Min Chul Jeong   +4 more
core   +1 more source

Colistin Resistance Mechanisms in Human and Veterinary Klebsiella pneumoniae Isolates

, 2022
Colistin (polymyxin E) is increasingly used as a last-resort antibiotic for the treatment of severe infections with multidrug-resistant Gram-negative bacteria.
Lisa Sedlaczek, Paul G. Higgins, Stephan Göttig, Higgins, Paul G., Manuela Tietgen, Christa Ewers, Kaspar, Heike, Ewers, Christa, Göttig, Stephan, Sedlaczek, Lisa, Heike Kaspar, Tietgen, Manuela   +11 more
core   +1 more source

Effect of Green‐Synthesized Silver Nanoparticles From Nepeta pogonosperma and Astrodaucus persicus on the Reduction of Bap Gene Expression in Strong Biofilm‐Producing Acinetobacter baumannii Clinical Isolates

MicrobiologyOpen, Volume 15, Issue 5, October 2026.
Green‐synthesized silver nanoparticles from Nepeta pogonosperma and Astrodaucus persicus significantly inhibit biofilm formation and downregulate bap gene expression in multidrug‐resistant clinical isolates of Acinetobacter baumannii. This eco‐friendly approach offers a promising strategy to combat antimicrobial resistance.
Maedeh Kakavan, Mehrdad Gholami, Mohammad Ahanjan, Mohammad Ali Ebrahimzadeh, Abolfazl Hossein Nataj, Tahoora Mousavi, Hamid Reza Goli   +6 more
wiley   +1 more source

Colistin resistance development following colistin-meropenem combination therapy versus colistin monotherapy in patients with infections caused by carbapenem-resistant organisms

, 2020
Background. We evaluated whether carbapenem-colistin combination therapy reduces the emergence of colistin resistance, compared to colistin monotherapy, when given to patients with infections due to carbapenem-resistant Gram-negative organisms.
Bernardo, M., Altunin, S., Bertolino, L., Koppel, F., Pafundi, P.C., Elbaz, M., Giurazza, R., Schwartz, D., Nutman, A., Giuffre, G., Mouton, J., Friberg, L., Antoniadou, A., Paul, M., Skiada, A., Benattar, Y.D., Daitch, V., Neuberger, A., Babich, T., Murino, P., Zampino, R., Andria, N., Raines, M., Kotsaki, A., Deliolanis, I., Atamna, H., Carmeli, Y., Cuccurullo, S., Dickstein, Y., Corcione, A., Durante-Mangoni, E., Kristoffersson, A., Bitterman, R., Karban, A., Daikos, G.L., Rognås, V., Adler, A., Andini, R., Iossa, D., Eliakim-Raz, N., Levi, I., Zak-Doron, Y., Rakovitsky, N., Friberg, L.E., Petersiel, N., Cavezza, G., Yahav, D., Galdo, M., Pavleas, I., Lellouche, J., the AIDA Study Group, Stern, A., Theuretzbacher, U., Mouton, J.W., Zusman, O., Leibovici, L., Zayyad, H., Cristinziano, A.   +57 more
core   +1 more source